Copaxone’s effect on MRI-monitored disease in relapsing MS is reproducible and sustained
- 22 October 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 59 (8) , 1284-1286
- https://doi.org/10.1212/wnl.59.8.1284
Abstract
All but 6% of the subjects with relapsing remitting MS who were randomly assigned to receive glatiramer acetate or placebo for the 9-month controlled phase of the European/Canadian MRI trial entered an open-label extension with quarterly clinical and MRI evaluations for another 9 months. There was a 54% reduction in the mean number of enhanced lesions for those converted from placebo to glatiramer acetate and an additional 24.6% reduction for those always on glatiramer acetate. Over the entire study the accumulated T2 disease burden was 34.2% less for those always on glatiramer acetate.Keywords
This publication has 4 references indexed in Scilit:
- Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”Neurology, 2001
- European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosisAnnals of Neurology, 2001
- Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disabilityNeurology, 1998
- A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple SclerosisNew England Journal of Medicine, 1987